Alpha 1 Antitrypsin Deficiency Treatment Market Report – Research, Industry Analysis Reports and Market Demands

Global Alpha 1 Antitrypsin Deficiency Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Alpha 1 Antitrypsin Deficiency Treatment by Indication
- 1.3.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Value Market Share by Indication in 2023
- 1.3.3 Augmentation Therapy
- 1.3.4 Cystic Fibrosis(CF)
- 1.3.5 Non-CF Bronchiectasis(NCFB)
- 1.3.6 Diabetes
- 1.3.7 Other
1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market by End Users
- 1.4.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users: 2019 Versus 2023 Versus 2030
- 1.4.2 COPD
- 1.4.3 Cystic Fibrosis(CF)
- 1.4.4 Non-CF Bronchiectasis(NCFB)
- 1.4.5 Diabetes
1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size & Forecast
1.6 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast by Region
- 1.6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region, (2019-2030)
- 1.6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2019-2030)
- 1.6.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2019-2030)
- 1.6.6 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2019-2030)
- 1.6.7 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size and Prospect (2019-2030)

2 Company Profiles

3 Market Competition, by Players

3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Alpha 1 Antitrypsin Deficiency Treatment by Company Revenue
- 3.2.2 Top 3 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share in 2023
- 3.2.3 Top 6 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share in 2023
3.3 Alpha 1 Antitrypsin Deficiency Treatment Market: Overall Company Footprint Analysis
- 3.3.1 Alpha 1 Antitrypsin Deficiency Treatment Market: Region Footprint
- 3.3.2 Alpha 1 Antitrypsin Deficiency Treatment Market: Company Product Type Footprint
- 3.3.3 Alpha 1 Antitrypsin Deficiency Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Indication

4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Value and Market Share by Indication (2019-2024)
4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Indication (2025-2030)

5 Market Size Segment by End Users

5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Consumption Value Market Share by End Users (2019-2024)
5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by End Users (2025-2030)

6 North America

6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Indication (2019-2030)
6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users (2019-2030)
6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
- 6.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Country (2019-2030)
- 6.3.2 United States Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 6.3.3 Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)

7 Europe

7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Indication (2019-2030)
7.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by End Users (2019-2030)
7.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
- 7.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Country (2019-2030)
- 7.3.2 Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 7.3.3 France Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 7.3.5 Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 7.3.6 Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)

8 Asia-Pacific

8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Indication (2019-2030)
8.2 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by End Users (2019-2030)
8.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region
- 8.3.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Region (2019-2030)
- 8.3.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 8.3.3 Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 8.3.5 India Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 8.3.7 Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)

9 South America

9.1 South America Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Indication (2019-2030)
9.2 South America Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by End Users (2019-2030)
9.3 South America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
- 9.3.1 South America Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)

10 Middle East & Africa

10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Indication (2019-2030)
10.2 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by End Users (2019-2030)
10.3 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
- 10.3.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)
- 10.3.4 UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size and Forecast (2019-2030)

11 Market Dynamics

11.1 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
11.2 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
11.3 Alpha 1 Antitrypsin Deficiency Treatment Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Chain
12.2 Alpha 1 Antitrypsin Deficiency Treatment Upstream Analysis
12.3 Alpha 1 Antitrypsin Deficiency Treatment Midstream Analysis
12.4 Alpha 1 Antitrypsin Deficiency Treatment Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.
According to our (Global Info Research) latest study, the global Alpha 1 Antitrypsin Deficiency Treatment market size was valued at US$ 2101 million in 2023 and is forecast to a readjusted size of USD 3766 million by 2030 with a CAGR of 8.8% during review period.
Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.
This report is a detailed and comprehensive analysis for global Alpha 1 Antitrypsin Deficiency Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Indication and by End Users. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Alpha 1 Antitrypsin Deficiency Treatment market size and forecasts, in consumption value ($ Million), 2019-2030
Global Alpha 1 Antitrypsin Deficiency Treatment market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Alpha 1 Antitrypsin Deficiency Treatment market size and forecasts, by Indication and by End Users, in consumption value ($ Million), 2019-2030
Global Alpha 1 Antitrypsin Deficiency Treatment market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Alpha 1 Antitrypsin Deficiency Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Alpha 1 Antitrypsin Deficiency Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring, Kamada Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Alpha 1 Antitrypsin Deficiency Treatment market is split by Indication and by End Users. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Indication and by End Users. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Alpha 1 Antitrypsin Deficiency Treatment market is split by Indication and by End Users. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Indication and by End Users. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Indication
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Other
Market segment by End Users
COPD
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Diabetes
Market segment by players, this report covers
Pfizer
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical Industries
Takeda
Baxter
Grifols
CSL Behring
Kamada Ltd
Chiesi Pharmaceuticals
Kedrion Group
Vertex Pharmaceuticals
ProMetic Life Sciences
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Alpha 1 Antitrypsin Deficiency Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Alpha 1 Antitrypsin Deficiency Treatment, with revenue, gross margin, and global market share of Alpha 1 Antitrypsin Deficiency Treatment from 2019 to 2024.
Chapter 3, the Alpha 1 Antitrypsin Deficiency Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Indication and by End Users, with consumption value and growth rate by Indication, by End Users, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Alpha 1 Antitrypsin Deficiency Treatment market forecast, by regions, by Indication and by End Users, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Alpha 1 Antitrypsin Deficiency Treatment.
Chapter 13, to describe Alpha 1 Antitrypsin Deficiency Treatment research findings and conclusion.

Buy now